Greg Walden, partner at McGuireWoods and senior advisor with McGuireWoods Consulting, recently discussed legal concerns, ethical considerations and policy around autonomous vehicles with the Corporate Counsel Business Journal.
In a Sept. 10 opinion piece for The Hill, McGuireWoods Consulting executive vice president and director, Frank Donatelli, compares the upcoming midterm elections and modern politics to a heavyweight fight.
Former Educator Touts Strong Legislative Affairs Background
Client Service, Business Growth Remain Top Priority
Five members of McGuireWoods Consulting’s Atlanta office were recognized in the James Magazine’s 2018 “Top Lobbyist” issue.
This Week: Labor-HHS Appropriations conference comes to agreement; hospitals sue over 340B implementation delay; Senate delays votes on opioids and gag clause because of hurricane; Maryland files suit to declare ACA constitutional
The Raleigh office could potentially lose power due to the impact from Hurricane Florence. If so, we will respond back to you as soon as possible. We wish safe travels to everyone evacuating from the storm and successful recovery after the storm.
This Week: Greg Walden Examines Legal and Ethical Ramifications of Driverless Cars | Government Looks to Streamline Federal Unmanned Technology Solutions | Committee Explores Future of Transportation While AV Bills Remain on Hold | Senate Commerce to Examine Consumer Privacy | Digital Citizens Alliance Holds Congressional Briefing on Social Media Platforms
In recent years, state emissions credit programs and policy have sought to incentivize only renewable electricity generation, leaving out other sources of zero-emissions generation.
This Week: House and Senate Work to Avoid Government Shutdown; Legislation on Gag Clauses Moving; Oral Arguments on ACA Individual Mandate Court Case Held
An overview of the upcoming week in Congress from the McGuireWoods Consulting Federal Public Affairs Team.
The Centers for Medicare and Medicaid Services (CMS) recently proposed to expand its site-neutral payment policy to clinic visits.
The House of Representatives approved the first major change to federal regulation of the over-the-counter drug industry in 40 years.